This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular). Embolization is a minimally invasive surgical technique performed under angiographic (imaging of blood vessels) guidance. Embolization therapy injects tiny particles into the arteries feeding tumors to cut off their blood supply which may help improve outcomes by preventing blood loss during surgery, reducing surgical times, and shrinking tumors or reducing recurrence.

开始日期2023-12-21

申办/合作机构

University of Washington

[+1]

NCT03631771 / Withdrawn临床4期

A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.

This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure.

开始日期2022-03-01

申办/合作机构

GE Healthcare Holdings, Inc.

[+2]

NCT05065073 / Recruiting临床4期IIT

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

The proposed study aims to compare (a) volume contrast administered for Optical Coherence Tomography (OCT) Imaging, (b) length of clear OCT images, and (c) electrocardiographic changes immediately after contrast injection between iso-osmolar and low-osmolar contrast agents. The proposed study is a prospective, single-centered, randomized controlled, study that will compare an iso-osmolar vs. a low-osmolar contrast agent in patients undergoing clinically indicated coronary OCT imaging. Each patient will be randomized to OCT acquisition.

开始日期2021-09-30

申办/合作机构

Minneapolis Heart Institute Foundation, Inc.

100 项与碘克沙醇相关的临床结果

登录后查看更多信息

100 项与碘克沙醇相关的转化医学

登录后查看更多信息

100 项与碘克沙醇相关的专利（医药）

登录后查看更多信息

895

项与碘克沙醇相关的文献（医药）

2024-05-01·Microvascular Research

Microvascular changes following exposure to iodinated contrast media in vitro. A qualitative comparison to serum creatinine concentrations in post-cardiac catheterization patients

Article

作者: Magnusson, Marine M M ; Rieger, Juliane ; Schüpbach, Gertraud ; Plendl, Johanna ; Kaessmeyer, Sabine ; Drews, Barbara ; Gerk, Ulrich ; Marin, Ilka

INTRODUCTIONContrast-associated acute kidney injury (CA-AKI) is characterized as a loss of renal function following radiological contrast media administration. While all contrast media induce variable changes in microvascular endothelial cells in vitro, only few studies report clinical significance of their findings. A comprehensive assessment of the effect of iodinated contrast media on the renal function in vitro and in vivo is essential. The aim of our study was to morphometrically quantify the effect of two different contrast media (Iobitridol and Iodixanol) on vascular endothelial capillaries in vitro and to analyze their effect on the renal function of patients who underwent cardiac catheterization including the intra-arterial administration of contrast media, by measuring serum creatinine concentration (SCr), a byproduct of muscle metabolism, primarily excreted by the kidneys. Our hypothesis suggests that conducting a qualitative comparison of both outcomes will enable identification of differences and similarities between in vitro and in vivo exposure.MATERIAL AND METHODSIn vitro, co-cultures of human dermal fibroblasts and human dermal microvascular endothelial cells forming capillary beds were exposed to a mixture of phosphate buffered saline and either Iobitridol, Iodixanol, or one of their supplements EDTA or Trometamol for 1.5 or 5 min. Negative control co-cultures were exposed exclusively to phosphate buffered saline. Co-cultures were either directly fixed or underwent a regeneration time of 1, 3 or 7 days. An artificial intelligence software was trained for detection of labeled endothelial capillaries (CD31) on light microscope images and measurements of morphometric parameters. In vivo, we retrospectively analyzed data from patients who underwent intra-arterial administration of contrast media and for whom SCr values were available pre- and post-contrast exposition (1, 3, and 7 days following procedure). Temporal development of SCr and incidence of CA-AKI were assessed. Both exposure types were qualitatively compared.RESULTSIn vitro, Iobitridol, Iodixanol and EDTA induced a strong decrease of two morphometric parameters after 3 days of regeneration. In vivo, a significant increase of SCr and incidence of CA-AKI was observed 3 days following procedure in the post-contrast media patients. No difference was observed between groups.DISCUSSIONTwo of the morphometric parameters were inversely proportional to the SCr of the patients. If the endothelial damages observed in vitro occur in vivo, it may result in renal hypoxia, inducing a loss of kidney function clinically translated into an increase of SCr. Further development of our in vitro model could allow closer replication of the internal structure of a kidney and bridge the gap between in vitro studies and their clinical findings.

2024-05-01·Coronary Artery Disease

Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial

Article

作者: Prakash, Gyan ; Yusuf, Jamal ; Mukhopadhyay, Saibal ; Safal, Safal ; Mehta, Vimal

IntroductionContrast-induced nephropathy (CIN) is a common complication after percutaneous coronary intervention (PCI). There is conflicting evidence regarding efficacy of nicorandil in CIN prevention. With respect to ranolazine, there is physiological possibility as well as data in animal study regarding its protective effect against CIN; there is, however, no human data till date.Aim and objectivesTo assess the efficacy of nicorandil and ranolazine in preventing CIN. The secondary endpoint was to measure difference in postprocedure acute kidney injury (AKI) incidence across groups. Also, patients were followed up till 6 months for major adverse events.Material and methodsThis single-center randomized controlled study included 315 patients of coronary artery disease with mild-to-moderate renal dysfunction undergoing elective PCI. Eligible patients were assigned to either nicorandil (n = 105), ranolazine (n = 105) or control group (n = 105) in 1 : 1 : 1 ratio by block randomization. All enrolled patients were given intravenous sodium chloride at rate of 1.0 mL/kg/h (0.5 mL/kg/h for patients with left ventricular ejection fraction <45%) from 6 h before procedure till 12 h after procedure. Iso-osmolar contrast agent (iodixanol) was used for all patients. In addition to hydration, patients in nicorandil group received oral nicorandil (10 mg, 3 times/d) and those in ranolazine group received oral ranolazine (1000 mg, 2 times/d) 1 day before procedure and for 2 days after PCI. Patients in control group received only hydration.ResultsTotal number of CIN was 34 (10.7%), which included 19 (18.1%) in control, 8 (7.6%) in nicorandil and 7 (6.6%) in ranolazine group. There was significant association of CIN reduction across groups (P = 0.012). On pairwise comparison also, there was significant benefit across control and ranolazine as well as control and nicorandil (P < 0.025). There was numerically higher incidence of AKI in controls; the difference, however, did not reach statistical significance after applying Bonferroni correction (P = 0.044). Over 6-month follow-up, adverse events were similar across groups.ConclusionWhile this study adds to existing literature that supports role for nicorandil in CIN prevention, the efficacy of ranolazine in protecting against CIN has been demonstrated in humans for the first time.

2024-03-01·The Journal of Allergy and Clinical Immunology: In Practice

Cutaneous Leukocytoclastic Vasculitis Induced by the Iodinated Contrast Media Iohexol With Cross-Reactivity to Iodixanol

Article

作者: Mija, Lorena Alexandra ; Filion, Charles Alexandre ; Picard, Matthieu ; Désy, Delphine

105

项与碘克沙醇相关的新闻（医药）

2024-05-13

·米内网

【重磅】倍特药业拿下30亿造影剂，百亿市场第六款新品

精彩内容近日，成都倍特药业的碘佛醇注射液获批上市，成为公司第六款造影剂。2023年在中国公立医院终端，碘佛醇注射液是造影剂TOP1产品，销售额超过了30亿元。目前公司还有4款造影剂新品报产在审，猛攻百亿市场。图1：成都倍特药业最新获批的产品来源：NMPA官网碘佛醇注射液为经血管用药的非离子、低渗透、水溶性、不透射线造影剂，作用机制为经血管注入后，造影剂流经的血管将变成不透光状态，从而可在X线下显影。米内网数据显示，目前碘佛醇注射液已有2家进口企业和3家国内药企（含倍特药业）获得生产批文。图2：碘佛醇注射液的销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，造影剂的市场规模在2023年达到了148亿元，同比增长了10.72%。碘佛醇注射液是造影剂TOP1产品，2023年在中国公立医疗机构终端的销售额突破30亿元。原研企业法国加柏的市场份额逐年下滑，在2023年仅剩4%左右，国产品牌大有可为。图3：成都倍特药业及子公司已上市的造影剂来源：米内网中国上市药品（MID）数据库2022年成都倍特药业的首款造影剂碘普罗胺注射液获批，2023年公司拿下了碘帕醇注射液和碘克沙醇注射液，今年以来钆贝葡胺注射液、钆特酸葡胺注射液、碘佛醇注射液陆续上市，公司的造影剂已累计有6款。2023年在中国公立医疗机构终端造影剂市场，碘普罗胺注射液是TOP4产品，碘帕醇注射液是TOP7产品，碘克沙醇注射液是TOP2产品，钆贝葡胺注射液是TOP16产品，钆特酸葡胺注射液是TOP9产品，本次获批的碘佛醇注射液是TOP1产品。图4：成都倍特药业及子公司报产在审的造影剂来源：米内网中国申报进度（MED）数据库成都倍特药业积极布局造影剂大品种，目前碘佛醇注射液还有两个受理号正在审评审批中，此外还有4款新品（指首次申报上市的产品）正在冲刺。其中钆特醇注射液和碘美普尔注射液目前的竞争企业数量（进口+国产）仅有2家，成都倍特药业有望争取国产第二家获批。若上述产品最终顺利获批，公司的造影剂产品矩阵将进一步扩大。资料来源：NMPA官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至5月13日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准医药出海一致性评价

2024-05-13

·信狐药迅

仿制药上市申请有14个品规发通知件；临床申请品种均默示许可| 新获批（5.6-5.12）

每周药品注册获批数据，分门别类呈现，一目了然。(5.6-5.12）小编收到有些用户反应，不想收到咱们每周文章的推送提醒，而有些用户又特别需要这个提醒，在小编强烈要求下，我们给力的程序员终于实现了可以关闭提醒的功能，这个绝对全网独一家喔，不想收到提醒的，只要在信狐药迅对话框内回复关键词“拒收文章提醒”，那么就可以不受推送的打扰啦!新药上市申请药品名称企业注册分类受理号TQB2450注射液正大天晴药业集团南京顺欣制药有限公司1CXSS2300003新药临床申请药品名称企业注册分类受理号TQ05105片正大天晴药业集团股份有限公司1CXHL2400232TQ05105片正大天晴药业集团股份有限公司1CXHL2400231SPH7485片上海医药集团股份有限公司1CXHL2400219SPH7485片上海医药集团股份有限公司1CXHL2400220SPH7485片上海医药集团股份有限公司1CXHL2400221SPH7485片上海医药集团股份有限公司1CXHL2400222ENN0403胶囊轶诺(浙江)药业有限公司1CXHL2400216ENN0403胶囊轶诺(浙江)药业有限公司1CXHL2400215HS-10382片江苏豪森药业集团有限公司1CXHL2400207HS-10382片江苏豪森药业集团有限公司1CXHL2400206SIPI6398片上海中泽医药科技有限公司1CXHL2400205SSS39注射剂沈阳三生制药有限责任公司1CXHL2400204INR101注射液云核医药(天津)有限公司1CXHL2400200ISM3412胶囊英矽智能科技(上海)有限公司1CXHL2400184ISM3412胶囊英矽智能科技(上海)有限公司1CXHL2400183ISM3412胶囊英矽智能科技(上海)有限公司1CXHL2400181GP681干混悬剂江西青峰药业有限公司1CXHL2400185BW-20507注射液杭州舶临医药科技有限公司1CXHL2400176JYP0066乳膏广州嘉越医药科技有限公司1CXHL2400167JYP0066乳膏广州嘉越医药科技有限公司1CXHL2400166JYP0066乳膏广州嘉越医药科技有限公司1CXHL2400165JYP0066乳膏广州嘉越医药科技有限公司1CXHL2400164JYP0066乳膏广州嘉越医药科技有限公司1CXHL2400163JYP0066乳膏广州嘉越医药科技有限公司1CXHL2400162BIOS2207浙江赛默制药有限公司2.2CXHL2400229BIOS2207浙江赛默制药有限公司2.2CXHL2400228GBI268注射液广州智耀生物科技有限公司2.2CXHL2400230注射用瑞卢戈利诺桥制药(成都)有限责任公司2.2CXHL2400194布立西坦注射液江西银涛药业股份有限公司3CYHL2400040糠酸莫米松富马酸福莫特罗吸入气雾剂长风药业股份有限公司3CYHL2400038酒石酸匹莫范色林胶囊华中药业股份有限公司3CYHL2400037JP001片北京慧宝源生物技术股份有限公司2.4;2.3CXHL2400202BAT1308注射液百奥泰生物制药股份有限公司1CXSL2400161注射用BAT8006百奥泰生物制药股份有限公司1CXSL2400162QX013N注射液江苏荃信生物医药股份有限公司1CXSL2400165注射用BL-B16D1成都百利多特生物药业有限责任公司1CXSL2400159LAE102注射液来凯医药科技(上海)有限公司1CXSL2400155CM383注射液康诺亚生物医药科技(成都)有限公司1CXSL2400154混合活化杀伤(MAK)免疫细胞注射液北京拓华伟业生物科技有限公司1CXSL2400119异体人源脂肪间充质干细胞注射液江苏得康生物科技有限公司1CXSL2400111RJK002注射液上海瑞吉康生物医药有限公司1CXSL2400117仿制药申请药品名称企业注册分类受理号酮咯酸氨丁三醇注射液福建天泉药业股份有限公司3CYHS2301619盐酸哌罗匹隆片四川科瑞德制药股份有限公司3CYHS2301594恩格列净二甲双胍缓释片上海汇伦江苏药业有限公司3CYHS2301339恩格列净二甲双胍缓释片上海汇伦江苏药业有限公司3CYHS2301337恩格列净二甲双胍缓释片上海汇伦江苏药业有限公司3CYHS2301336双氯芬酸钠注射液北京世桥生物制药有限公司3CYHS2301043盐酸多巴胺注射液山东达冠医药科技有限公司3CYHS2300596盐酸多巴胺注射液山东达冠医药科技有限公司3CYHS2300594阿齐沙坦片浙江诺得药业有限公司3CYHS2300009国;CYHS2300009盐酸奥洛他定颗粒南京明生医药有限公司3CYHS2202150国;CYHS2202150盐酸丙卡特罗颗粒安徽百奥药业有限公司3CYHS2201846国;CYHS2201846盐酸苯达莫司汀注射液齐鲁制药有限公司3CYHS2201798国;CYHS2201798盐酸多柔比星脂质体注射液常州吾合生物医药有限责任公司3CYHS2201562国;CYHS2201562盐酸多柔比星脂质体注射液常州吾合生物医药有限责任公司3CYHS2201561国;CYHS2201561低钙腹膜透析液(乳酸盐-G2.5)安徽丰原药业股份有限公司3CYHS2201233国;CYHS2201233低钙腹膜透析液(乳酸盐-G1.5)安徽丰原药业股份有限公司3CYHS2201232国;CYHS2201232注射用甲氨蝶呤上海上药睿尔药品有限公司3CYHS2102209国;CYHS2102209卡络磺钠注射液康普药业股份有限公司3CYHS2101509国;CYHS2101509氟比洛芬凝胶贴膏江苏万高药业股份有限公司4CYHS2301698盐酸罗匹尼罗缓释片江西金水宝制药有限公司4CYHS2301463碘克沙醇注射液通用电气药业(上海)有限公司4CYHS2301166硝酸异山梨酯注射液河北东圣科宇医药科技有限公司4CYHS2300695氢溴酸伏硫西汀片福建省闽东力捷迅药业股份有限公司4CYHS2300559泮托拉唑钠肠溶片寿光富康制药有限公司4CYHS2300571他达拉非片安徽贝克生物制药有限公司4CYHS2300404多索茶碱注射液赤峰万泽药业股份有限公司4CYHS2300257盐酸帕罗西汀肠溶缓释片山东京卫制药有限公司4CYHS2300150盐酸帕罗西汀肠溶缓释片山东京卫制药有限公司4CYHS2300149二甲双胍维格列汀片(III)浙江诺得药业有限公司4CYHS2300142地氯雷他定片合肥国药诺和药业有限公司4CYHS2201952国;CYHS2201952沙库巴曲缬沙坦钠片常州制药厂有限公司4CYHS2201907国;CYHS2201907沙库巴曲缬沙坦钠片常州制药厂有限公司4CYHS2201906国;CYHS2201906替米沙坦氢氯噻嗪片南京海纳医药科技股份有限公司4CYHS2201841国;CYHS2201841盐酸二甲双胍缓释片河南羚锐制药股份有限公司4CYHS2201750国;CYHS2201750注射用美罗培南江苏睿实生物科技有限公司4CYHS2201715国;CYHS2201715注射用美罗培南江苏睿实生物科技有限公司4CYHS2201714国;CYHS2201714头孢泊肟酯片齐鲁制药有限公司4CYHS2201687国;CYHS2201687盐酸托莫西汀口服溶液长兴制药股份有限公司4CYHS2201404国;CYHS2201404盐酸帕罗西汀肠溶缓释片北京北陆药业股份有限公司4CYHS2201525国;CYHS2201525复方聚乙二醇电解质散(III)浙江诺得药业有限公司4CYHS2201517国;CYHS2201517吸入用乙酰半胱氨酸溶液扬子江药业集团江苏紫龙药业有限公司4CYHS2201444国;CYHS2201444苯磺酸左氨氯地平片平光制药股份有限公司4CYHS2200990国;CYHS2200990苯磺酸左氨氯地平片平光制药股份有限公司4CYHS2200989国;CYHS2200989注射用硫酸艾沙康唑江苏奥赛康药业有限公司4CYHS2200985国;CYHS2200985盐酸多奈哌齐口腔崩解片迪沙药业集团有限公司4CYHS2200968国;CYHS2200968盐酸多奈哌齐口腔崩解片迪沙药业集团有限公司4CYHS2200967国;CYHS2200967阿普米司特片江苏知原药业股份有限公司4CYHS2200944国;CYHS2200944阿普米司特片江苏知原药业股份有限公司4CYHS2200942国;CYHS2200942他达拉非片浙江康恩贝制药股份有限公司4CYHS2200884国;CYHS2200884碘佛醇注射液成都倍特药业股份有限公司4CYHS2200395国;CYHS2200395进口申请药品名称企业注册分类受理号注射用盐酸曲拉西利G1 Therapeutics, Inc.5.1JXHS2300075吡仑帕奈片Eisai Europe Limited5.1JXHS2300026吡仑帕奈片Eisai Europe Limited5.1JXHS2300025卡替拉韦注射液ViiV Healthcare Pty Ltd.5.1JXHS2200099国;JXHS2200099卡替拉韦钠片ViiV Healthcare Pty Ltd.5.1JXHS2200098国;JXHS2200098重组人促卵泡激素δ注射液辉凌医药咨询(上海)有限公司3.1JXSS2100014国;JXSS2100014重组人促卵泡激素δ注射液辉凌医药咨询(上海)有限公司3.1JXSS2100013国;JXSS2100013重组人促卵泡激素δ注射液辉凌医药咨询(上海)有限公司3.1JXSS2100012国;JXSS2100012盐酸昂丹司琼注射液Gland Pharma Limited5.2JYHS2000049国;JYHS2000049PF-07220060Pfizer Inc.1JXHL2400059PF-07220060Pfizer Inc.1JXHL2400058PF-07220060Pfizer Inc.1JXHL2400057注射用JR8603JiaRay Pharmaceuticals, Inc.1JXHL2400043镥[177Lu]Lu-NeoB注射液Novartis Pharma AG1JXHL2400032米罗那非片AriBio Co., Ltd.2.4JXHL2400048米罗那非片AriBio Co., Ltd.2.4JXHL2400047甲磺酸贝舒地尔片Kadmon Pharmaceuticals, LLC2.4JXHL2400045布地奈德硫酸沙丁胺醇吸入气雾剂AstraZeneca Pharmaceuticals LP2.4JXHL2400036注射用BL-8040冻干粉BioLineRx Ltd.5.1JXHL2400046DE-117B滴眼液Santen Pharmaceutical Co., Ltd.5.1JXHL2400033盐酸羟甲唑啉滴眼液Santen Pharmaceutical Co., Ltd.5.2JYHL2400001MEDI5752AstraZeneca AB1JXSL2400055Amlitelimab注射液Sanofi-Aventis Recherche & Developpement1JXSL2400054Amlitelimab注射液Sanofi-Aventis Recherche & Developpement1JXSL2400053AMG 451Amgen Inc.1JXSL2400047Itepekimab注射液Sanofi-Aventis Recherche & Developpement1JXSL2400044中药相关申请药品名称企业注册分类受理号宝心艾维西木口服液新疆维吾尔药业有限责任公司4CYZL2400001注：灰色字体部分结论为不批准或收到通知件；

申请上市临床申请

2024-04-21

·北陆药业

北陆药业一季度业绩开门红收入扣非净利润均增长

近日，北陆药业（300016）发布《2023年年度报告》和《2024年一季度报告》。2023年公司受多重因素影响，收入虽然持续上涨，但全年净利润出现亏损。随着公司各项改革的深入推进，2024年一季度公司业绩迎来开门红！收入、扣非后净利润同比均实现增长。一季度扣非净利润增速超30%2024年一季度公司营业收入达到20,750.61万元，同比增长10.35%，公司主业呈现稳健增长势头。归属于上市公司股东的扣除非经常性损益的净利润达1,144.64万元，同比上涨32.95%，充分体现公司核心业务的复苏和盈利能力的提升。受公司持有的以公允价值计量的金融工具在报告期末公允价值波动的影响，报告期内归属于上市公司股东的净利润同比下降8.35%。23年研发投入1.22亿增幅超20%根据公司披露的年报显示，近两年北陆药业一直推行各项改革措施， 2022年起，公司已对营销体系进行了全面改革，从目前收入端的业绩增速来看，已初见成效。2023年公司继续全面整合研发资源，组建药政中心和项目管理中心，对研发项目、技术转移、注册和临床等业务进行统一管理；公司将北陆研究院与北京艾湃克斯医药研发有限公司（原北陆益康医药研发有限公司）进行机构整合，北陆研究院整体并入艾湃克斯，组成更加高效、专业的研发机构。按照公司发展战略，艾湃克斯重新调整定位，在承担部分公司战略布局的项目和任务的同时，也将积极面向市场，承接更多业务。年报显示，公司2023年整体研发投入达到12,232.89万元，同比增长22.62%。海外业务表现亮眼收入同比增长133%除了研发外，公司2023海外市场拓展表现亮眼。报告期内，北陆药业和海昌药业海外市场收入总计达到1.15亿元，同比增长132.98%。取得如此业绩主要有以下几个原因:首先，2023年北陆对比剂制剂在智利政府招标中标、在肯尼亚、塔吉克斯坦等国取得注册证书，公司对比剂产品客户数量持续增加，目前尚有多个国家正在注册、洽谈中；其次，出口的产品更加丰富，制剂方面，不仅碘海醇注射液、钆喷酸葡胺注射液覆盖的市场拓展速度加快，碘克沙醇注射液也取得了海外订单，实现了国际化；沧州工厂生产的钆类原料药等产品的海外市场拓展也表现出良好的发展势头；第三，已在国际市场奠定基础的海昌药业2023年进一步开拓了韩国、伊朗等市场，持续增加的客户和市场为海昌药业海外碘造影剂的营收增长提供了动力，收入出现较大增幅。坚定“中成药战略” 打造“第二增长曲线”公司以“中国医药制造百强企业”为中长期发展目标，坚定落实“化药+中药”双轮驱动的公司战略。2023年公司旗下陆芝葆药业有限公司已在安徽省亳州市竞拍取得143.335亩国有土地使用权，正有序推进第四生产基地的建设工作，为全面提升公司颗粒剂、片剂、胶囊剂和丸剂等产品的产能，实现未来的中成药领域布局奠定坚实基础。近日，公司正式公告收购承德天原药业，本次天收购完成后，公司“化药+中药”双轮驱动的战略正式落地。除北陆原有的独家原研抗焦虑中药九味镇心颗粒外，公司将新增58个中药批文，其中：国家医保品种44个，国家基药品种18个，OTC品种41个，涉及清热解毒类、胃肠类、感冒类、补益类、活血止痛类等多个领域；继九味镇心颗粒之后，公司拥有了第二款全国独家品种、国家医保乙类品种金莲花颗粒，该产品同时为OTC乙类,全年收入近亿元。天原药业的股权收购工作仍在积极推进中，公司将全面推进投后整合、业务赋能工作，将其纳入公司集团化的运营体系中，通过营销、采购、生产、管理等多方面的赋能和协同，提升天原药业的经营能力和业绩，实现快速补充产品线、拓展新赛道和新渠道、增厚公司业绩的目标，为公司的持续发展注入新的动力。

财报高管变更

100 项与碘克沙醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01474	碘克沙醇	V08AB09	DB01249

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
造影剂	美国	GE Healthcare, Inc.	1997-08-29
冠心病	美国	GE Healthcare, Inc.	1996-03-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	临床3期	美国	GE Healthcare Holdings, Inc.	2006-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00926562 (DIRECT, Pubmed \| EuroIntervention)	临床4期	-	562	iopromide	廠鏇餘鏇顧簾鑰夢衊顧(顧遞獵鑰觸廠壓窪簾襯) = 獵壓鹽繭憲鹹憲廠淵淵襯簾獵網製淵觸壓鹽糧 (鏇顧獵壓鑰齋艱鹹簾夢 ) 更多	-	2012-11-22
				iodixanol	廠鏇餘鏇顧簾鑰夢衊顧(顧遞獵鑰觸廠壓窪簾襯) = 願醖膚蓋醖鏇繭製鬱構襯簾獵網製淵觸壓鹽糧 (鏇顧獵壓鑰齋艱鹹簾夢 ) 更多
NCT00793182 (CTgov)	临床4期	肾功能不全	6	iodixanol (Iodixanol)	鏇觸鑰淵簾築鏇範齋遞(醖鑰選鹹築繭積夢襯構) = 夢遞願顧衊糧廠範膚襯範網顧鏇艱夢繭襯淵顧 (簾製遞構觸遞築憲鏇簾, 築糧網壓壓憲衊範蓋築 ~ 顧夢憲憲糧積窪糧觸鹽) 更多	-	2017-09-29
				ioversol (IoversoI)	鏇觸鑰淵簾築鏇範齋遞(醖鑰選鹹築繭積夢襯構) = 簾壓網衊壓艱範簾簾構範網顧鏇艱夢繭襯淵顧 (簾製遞構觸遞築憲鏇簾, 願願齋繭網憲襯衊齋膚 ~ 窪淵觸鬱齋鏇鬱網壓範)
AAAAI2010	N/A	迟发型超敏反应 IL-2 \| IFN-γ \| IL-6 ... 更多	-	Iodixanol	醖壓窪齋淵積積繭襯繭(範醖鑰鑰範艱醖簾齋網) = an increase of CD40 expression were induced by iodixanol 網製齋鏇簾鹽積選蓋構 (糧簾憲觸繭壓襯築鹹鏇 ) 更多	-	2010-02-01
NCT02171247 (CTgov)	临床3期	-	35	Visipaque 320 (Visipaque 320)	鹹憲鑰餘鬱積蓋積餘鬱(顧選糧觸簾顧膚獵構憲) = 膚餘鹹壓齋憲築簾積餘獵餘夢齋壓餘鏇壓觸蓋 (淵襯壓衊製鹹膚鹽觸醖, 鬱構鑰積積網鬱醖鏇壓 ~ 衊顧構網鹹夢顧襯選廠) 更多	-	2014-08-15
				Isovue 370 (Isovue 370)	鹹憲鑰餘鬱積蓋積餘鬱(顧選糧觸簾顧膚獵構憲) = 壓鬱壓觸獵鹽餘獵簾壓獵餘夢齋壓餘鏇壓觸蓋 (淵襯壓衊製鹹膚鹽觸醖, 網繭夢選糧製艱願網憲 ~ 鹽糧鹽遞網繭範遞糧範) 更多
NCT01848899 (CTgov)	临床4期	冠心病 \| 血栓形成	100	Bivalirudin+Ioxaglate (Ioxaglate Arm)	廠艱憲獵願選鏇夢憲壓(積衊顧壓範製襯夢襯選) = 鹽餘築憲襯遞顧醖衊襯鹹襯餘遞壓積憲鹽壓鏇 (蓋衊襯衊廠糧淵繭夢網, 壓廠淵廠鹽鹽選構餘鹹 ~ 製簾鹹網繭憲製窪構襯) 更多	-	2016-04-06
				Bivalirudin+Iodixanol (Iodixanol Arm)	廠艱憲獵願選鏇夢憲壓(積衊顧壓範製襯夢襯選) = 膚獵範鹹鹽醖鹽鬱淵遞鹹襯餘遞壓積憲鹽壓鏇 (蓋衊襯衊廠糧淵繭夢網, 築顧壓蓋蓋鹽鹹鹹製醖 ~ 廠鬱壓獵襯鏇遞齋壓築) 更多
AAAAI2018	N/A	造影剂	7	Iomeprol	願夢選網選積廠淵艱遞(選憲餘鹹觸壓鬱獵夢餘) = 膚製簾積糧鹽簾廠鹽窪簾膚醖夢簾範觸醖壓憲 (蓋製願衊憲夢願顧製範 )	不佳	2018-02-01
				Iohexol	願夢選網選積廠淵艱遞(選憲餘鹹觸壓鬱獵夢餘) = 鹹網觸獵觸膚糧夢簾廠簾膚醖夢簾範觸醖壓憲 (蓋製願衊憲夢願顧製範 )
NCT00209417 (CTgov)	临床4期	肾功能不全 \| 糖尿病	656	Iodixanol 320-Arm 1 (Iodixanol 320-Arm 1)	顧網醖製簾鹹蓋夢遞鹹(淵膚餘鹹壓齋壓衊願製) = 糧範艱築糧願艱獵膚製糧餘築選衊遞醖製艱餘 (遞餘淵鹽膚願鑰艱範憲, 窪築鹽積齋窪範淵構膚 ~ 衊鑰鬱顧淵鑰夢壓鑰鹹) 更多	-	2014-10-10
				Iopamidol 300-Arm 2 (Iopamidol 300-Arm 2)	顧網醖製簾鹹蓋夢遞鹹(淵膚餘鹹壓齋壓衊願製) = 構觸鹹淵膚衊積製構鹽糧餘築選衊遞醖製艱餘 (遞餘淵鹽膚願鑰艱範憲, 範鏇壓遞範製積遞簾簾 ~ 築選艱鹹築醖構壓廠鬱) 更多
AAAAI2011	N/A	造影剂	78	Iomeprol	製淵獵艱鬱鏇鏇願淵壓(壓鑰鬱構網築築遞艱壓) = 築鹹淵積鑰鹽鹹衊遞蓋築遞衊積築淵醖願餘遞 (遞淵顧築鹹鹹鬱觸襯齋 ) 更多	积极	2011-02-01
				Iodixanol	製淵獵艱鬱鏇鏇願淵壓(壓鑰鬱構網築築遞艱壓) = 鬱衊鹹構襯製壓醖夢構築遞衊積築淵醖願餘遞 (遞淵顧築鹹鹹鬱觸襯齋 ) 更多
AAAAI2009	N/A	造影剂	-	Iopamidol	艱齋醖顧壓艱簾積觸醖(獵構鏇鏇淵糧選顧齋鹹) = 簾願簾醖憲蓋蓋鹹範鏇鏇醖夢網襯遞鑰網願選 (顧壓糧淵淵齋夢醖鏇鑰 )	-	2009-03-17
				Ioversol	艱齋醖顧壓艱簾積觸醖(獵構鏇鏇淵糧選顧齋鹹) = 鹹壓襯遞製鹹製觸顧構鏇醖夢網襯遞鑰網願選 (顧壓糧淵淵齋夢醖鏇鑰 )
NCT03119662 (CTgov)	临床4期	动脉瘤 \| 慢性肾病	4	Visipaque (Visipaque™: Contrast-Enhanced Computed Tomography (CECT))	醖積壓憲顧鏇窪齋蓋積(襯鹽範製廠餘淵餘壓廠) = 膚廠願淵夢夢鹽觸簾窪膚獵遞鏇網構衊製夢餘 (憲淵範網顧鑰築鑰衊夢, 鑰蓋鹽窪顧壓願觸觸積 ~ 襯齋襯構夢選觸選蓋憲) 更多	-	2019-12-17
				Placebos (Saline: Non-Enhanced Computed Tomography (NECT))	醖積壓憲顧鏇窪齋蓋積(襯鹽範製廠餘淵餘壓廠) = 築衊顧築獵積糧淵淵糧膚獵遞鏇網構衊製夢餘 (憲淵範網顧鑰築鑰衊夢, 窪願鹽鬱鑰鑰艱簾願壓 ~ 選餘夢繭觸淵鬱願築糧) 更多